Increasing concentrations of serum cholesterol, and particularly low-density lipoprotein (LDL) cholesterol, are a major risk factor for coronary heart disease. '-3 In the past the association between cholesterol and coronary heart disease has been underestimated because of regression dilution bias and surrogate dilution effect.4 After correction for these factors it has been calculated from international studies that a difference in serum cholesterol concentrations of 0.6 mmol/l is associated with a reduction in the risk of coronary heart disease of 25-30%. 4 Most of the international variance in coronary heart disease can be explained by differences in serum cholesterol. Analysis of the observational cohort studies shows that a difference of 0.6 mmol/l in serum cholesterol is associated with a difference in mortality from coronary heart disease of 54% at age 40 years and 39% at age 50 years. 4 The controlled clinical trials of cholesterol lowering support the epidemiological data with a 25% reduction in coronary heart disease for a 0.6 mmol/l cholesterol reduction after five years.5 Strong support for the benefits of reducing cholesterol concentrations has come from a recent secondary prevention trial using the hydroxy-methylglutaryl coenzyme A reductase inhibitor, simvastatin. 6 In this trial, the relative risk for death due to coronary heart disease in the treated group was 0.58 (95% CI 0.46-0.73).
Coronary heart disease risk prediction in the individual is improved with knowledge of the circulating concentrations of high-density lipoprotein (HDL) cholesterol, and triglycerides. Data from the PROCAM study7 and the placebo group of the Helsinki Heart Study8 point to the high risk ofcoronary heart disease in individuals with LDIJHDL ratios greater than five and with hypertriglyceridaemia. The major beneficial effect of the fibrate gemfibrozil in the Helsinki study was seen in this patient group.8
In previous studies both ciprofibrate9-'5 and bezafibrate16-9 have effected reductions in triglyceride and LDL-cholesterol levels and increases in HDL-cholesterol levels; these studies give indirect evidence that ciprofibrate is a more potent lipid-lowering agent than bezafibrate. In the present study the efficacy and safety of ciprofibrate (100 mg) and a sustained-release formulation of bezafibrate (Bezalip Mono, 400 mg) were directly compared in patients with type IIa or IIb hyperlipidaemia in order to confirm this evidence.
Patients and methods

PATIENTS
The study was a randomised, open, parallelgroup study performed in general practice.
Indications for treatment
Patients were selected from those identified as being hyperlipidaemic during routine consultations at their general practice. A total of 346 patients were screened, of whom 190 were eligible for randomisation, with data from 174 patients (76 men and 98 women with an average age of 56 years) being statistically analysed. All patients had Fredrickson type II primary hyperlipidaemia (cholesterol > 6.5 mmol/l) and were within 25% of their ideal weight according to Metropolitan Life standard insurance tables. One hundred and seventeen (58 on ciprofibrate, 59 on bezafibrate) of the patients in the study had type Ha hyperlipidaemia (cholesterol > 6.5 mmol/l, triglycerides<2.3 mmol/l). The Patients underwent an initial six-week prestudy screen and were instructed by their general practitioners to adhere to the standard lipid-lowering diet recommended by the European Atherosclerosis Society2" throughout the study. Compliance with diet was checked by questionnaire periodically during the study. This was followed by a four-week baseline stabilisation period during which dietary compliance was confirmed and eligibility for entry into the study was re-assessed. If during this period total cholesterol concentrations fluctuated by more than 15%, or triglyceride concentrations by more than 20%, patients underwent a further four weeks of baseline stabilisation and were then re-assessed for entry into the study. Patients were randomised according to a code generated by SAS® software (SAS Institute Inc, Cary, NC). A full clinical and cardiovascular examination was performed following the pre-study screen. Lipid concentrations, haematological and biological parameters were analysed after the prestudy screen, baseline stabilisation, and after four and eight weeks of treatment. Study treatment was given with the evening meal.
ETHICAL CONSIDERATIONS Approval for the study was given by the Royal College of General Practitioners Ethics Committee. Each investigator obtained approval from their local ethics committee before commencing the study. The trial was monitored according to Good Clinical Practice.
The study was conducted in accordance )Vith the Declaration of Helsinki and each patient gave written informed consent prior to enrolment into the study.
LABORATORY METHODS
Blood samples were obtained after an overnight fast and analysed by a central laboratory. In-house testing by the central laboratory confirmed that the analytes measured were stable for up to three days at ambient temperature. Total serum cholesterol and triglycerides were measured using an ICSI Summit Analyser. HDL-Cholesterol was measured after precipitation of VLDL-and LDLcholesterol with dextran sulphate -MgCl2. 22 The coefficient of variation of the laboratory assays was less than 3% for total cholesterol and triglycerides, and less than 5% for HDLcholesterol. LDL-Cholesterol was calculated from triglyceride, total and HDL-cholesterol values using the Decreases in LDL-cholesterol with concomitant increases in HDL-cholesterol produced favourable changes in the LDIJHDL-cholesterol ratio for both treatments. Ciprofibrate gave a mean reduction in the LDIJHDL ratio of 1.74 compared with a reduction of 1.63 for bezafibrate, although the difference was not significant.
The percentage change in total cholesterol, LDL-cholesterol, HDL-cholesterol and serum triglycerides differed between the sexes, females having a larger response than males with both treatments. The differences were not statistically different as determined by a test of treatment-by-sex interaction. However, the study was not designed to determine such sex differences.
Comparisons of changes in lipid parameters between type IIa and IIb hyperlipidaemics are shown in table 3. In all cases differences between drugs and between type IIa and IIb patients were nonsignificant. For both treatments, a greater percentage reduction from baseline in total serum cholesterol and LDLcholesterol was seen in type IIa patients compared with type IIb patients. Decreases in group.bmj.com on October 14, 2017 -Published by http://pmj.bmj.com/ Downloaded from total serum triglycerides, and increases in HDL-cholesterol, were greater for type IIb patients with both treatments.
The group randomised to ciprofibrate 100 mg/day were continued on treatment for an additional eight weeks at a higher dosage of 200 mg/day. The concentrations of total serum cholesterol, LDL-cholesterol and serum triglycerides were further reduced to 5.85 mmol/l, 3.88 mmolIl and 1.20 mmol/l, respectively. Changes in total serum cholesterol and LDLcholesterol were significantly different (p=0.0001 in both cases) from week eight results. The mean concentration of HDLcholesterol (1.41 mmol/l) was slightly, although not significantly, reduced from that observed at week eight.
TOLERABILITY
A total of 19 adverse events considered likely to be related to study drug were reported by 13 patients during the eight-week trial period. Six patients on ciprofibrate reported nine events and seven patients on bezafibrate reported 12 events, with headache the most common event. None of these events was severe. Four of these patients (two from each treatment group) withdrew from the study because of adverse events. Withdrawals were due to alopecia (ciprofibrate), somnolence combined with fever (ciprofibrate), headache (bezafibrate), and a combination of rash, nausea, vomiting and oedema (bezafibrate). Another two patients from each group withdrew for reasons not considered likely to be related to study drug.
There were no clinically significant changes (more than three times the upper limit of normal) in urea, creatinine, aspartate aminotransferase, or alanine aminotransferase, or in any haematological parameters during treatment with either drug.
A large decrease in alkaline phosphatase concentrations was observed with both treatments. The The LDL'HDL-cholesterol ratio was significantly reduced by both drugs and the reduc-tion observed with ciprofibrate (5.1 to 3.3) confirms the findings of an earlier study by Illingworth et ar who observed a change in the ratio from 5.1 to 3.5. Both drugs were well tolerated. Only two patients from each treatment group withdrew from the study because of adverse events considered likely to be related to study drug. Increases in creatine phosphokinase concentrations have been observed previously in studies of fibrates and HMG-CoA reductase inhibitors.27"28 In this study there was a significantly greater increase in creatine phosphokinase with ciprofibrate, but the changes were not associated with symptoms and no clinically significant elevations were observed. There were no cases of myositis. As expected, alkaline phosphatase concentrations were decreased.
Recent results from the Bezafibrate Coronary Atherosclerosis Intervention Trial (BE-CAIT) reported in Scrip show that progression of atheroma was significantly reduced by bezafibrate. It remains to be shown whether more potent fibrates, such as ciprofibrate, will have a greater effect in regressing atherosclerotic plaques, due to their more marked LDL-lowering ability compared with bezafibrate.
In summary, both drugs produced beneficial changes in the plasma lipid profile. Based on current available information it is believed that these changes would be associated with a substantial reduction of coronary heart disease risk. Ciprofibrate was significantly more effective in reducing cholesterol, triglycerides and LDL-cholesterol.
